pufa 20:5c

PUFA 20:5c, commonly referred to as eicosapentaenoic acid (EPA), is a long‑chain omega‑3 polyunsaturated fatty acid with 20 carbon atoms and five cis double bonds. Chemically abbreviated as 20:5 n‑3, EPA is one of the principal marine omega‑3 fatty acids, along with docosahexaenoic acid (DHA). These fats are considered conditionally essential: while the body can synthesize small amounts from alpha‑linolenic acid (ALA), the conversion rate is limited, making direct dietary EPA important to achieve optimal physiological effects. EPA was first identified in the early 20th century during studies of fish oil, and subsequent research in populations with high fish consumption—such as the Greenland Inuit—revealed associations with lower rates of cardiovascular and inflammatory diseases. At the molecular level, EPA incorporates into phospholipid membranes and influences membrane fluidity, receptor behavior, and cell signaling. It serves as a precursor to a class of signaling molecules called eicosanoids, which include prostaglandins, leukotrienes, and thromboxanes. These metabolites are less pro‑inflammatory compared with those derived from omega‑6 fatty acids, providing a biochemical basis for EPA’s anti‑inflammatory effects. Unlike saturated fats, polyunsaturated fatty acids like EPA have multiple double bonds, which affect their physical and chemical properties, including susceptibility to oxidation and specific roles in cell biology. EPA is primarily obtained from marine sources such as fatty fish, fish oils, and certain algal oils, though trace amounts can also be found in some meats and eggs from animals fed omega‑3 rich diets. Given its involvement in numerous physiological processes, EPA plays a vital role in maintaining health across the cardiovascular, immune, and central nervous systems.

EPA (PUFA 20:5c) plays multifaceted roles in human health through anti‑inflammatory, cardiovascular, and neurological mechanisms. Its anti‑inflammatory action stems from its role as a substrate for the synthesis of eicosanoids that are less pro‑inflammatory compared with those formed from omega‑6 fatty acids. This shift in eicosanoid balance can reduce systemic inflammation and influence chronic disease pathways, particularly in cardiovascular disorders and autoimmune conditions. Cardiovascular benefits are among the most studied effects of EPA. It helps lower circulating triglyceride levels, a recognized risk factor for atherosclerosis and coronary artery disease. Several clinical trials and meta‑analyses have demonstrated that supplemental EPA, especially at doses of 1–4 grams per day, can reduce triglycerides by 20–30%. EPA also influences other aspects of lipid metabolism, potentially increasing HDL cholesterol and modifying LDL particle size towards less atherogenic forms. Beyond lipids, EPA may modestly reduce blood pressure and improve endothelial function, contributing to overall heart health. Specific research published in journals such as the Journal of the American Heart Association points to benefits of combined EPA and DHA intake of 3 grams per day in lowering blood pressure among hypertensive individuals. In addition to cardiovascular outcomes, EPA has been investigated for its potential to support brain health and mood regulation. Some systematic reviews suggest that EPA‑dominant formulations may reduce symptoms of depression, possibly through modulation of neuronal membrane composition and inflammatory mediators in the brain. EPA also plays a role in immune modulation. Its incorporation into immune cell membranes alters signaling pathways related to cytokine production, which can impact conditions characterized by chronic inflammation, such as rheumatoid arthritis and inflammatory bowel disease. Although individual studies vary, many systematic reviews collectively indicate that omega‑3 fatty acids can reduce markers of inflammation, such as C‑reactive protein (CRP) and interleukin‑6, providing a biochemical basis for observed clinical improvements. EPA’s influence on cell membrane dynamics and signaling also extends to the central nervous system. While DHA is more abundant in brain tissue, EPA contributes to neural function and may affect mood, learning, and cognition indirectly through anti‑inflammatory pathways. Taken together, EPA’s biological effects encompass multiple organ systems, underscoring its importance as part of a balanced diet rich in marine omega‑3 fatty acids.

Unlike vitamins and minerals, EPA does not have a formally established Recommended Dietary Allowance (RDA) by the NIH Office of Dietary Supplements. Instead, intake recommendations focus on combined EPA and DHA due to their shared roles in health. The Food and Nutrition Board of the National Academies sets Adequate Intakes (AIs) for total omega‑3 fatty acids (primarily ALA), but no separate RDA exists for EPA alone. Expert organizations, including the American Heart Association and dietary guidelines in the U.S., generally recommend that adults consume at least 250–500 mg of combined EPA and DHA per day through diet or supplements to support cardiovascular health. Some guidelines suggest that individuals with coronary heart disease may benefit from approximately 1 gram of EPA+DHA daily, while those with elevated triglycerides might require higher doses, up to 2–4 grams per day under clinical supervision. For infants and young children, recommendations are less specific for EPA and focus more on total omega‑3 intake. During pregnancy and lactation, particular emphasis is placed on DHA for fetal brain and eye development, though EPA continues to contribute to maternal and infant health through modulation of inflammation and lipid metabolism. Dietary intake of EPA varies widely based on consumption patterns; individuals who consume fatty fish such as salmon, mackerel, sardines, or herring several times per week can easily meet or exceed EPA+DHA recommendations. Factors that influence EPA needs include age, sex, health status, and presence of chronic conditions such as cardiovascular disease or inflammatory disorders. Given the lack of a formal RDA, clinicians often individualize recommendations based on dietary habits, biomarkers such as the omega‑3 index, and specific health goals. In practice, achieving EPA intake within the context of a heart‑healthy diet that includes at least two servings of fatty fish per week aligns with expert guidance and contributes to meeting recommended EPA+DHA targets.

Clinical deficiency of EPA as a singular nutrient is uncommon in populations consuming diverse diets, but low intakes of marine omega‑3 fatty acids can lead to suboptimal tissue levels and functional consequences. Because EPA and DHA share metabolic pathways and often co‑occur in food sources, deficiency is typically framed in terms of inadequate omega‑3 status rather than isolated EPA deficiency. Low omega‑3 status can be assessed indirectly through biomarkers such as the omega‑3 index, which reflects the percentage of EPA+DHA in red blood cell membranes; values below 4% are generally considered low and associated with higher cardiovascular risk compared with values above 8%. Symptoms associated with low EPA and overall omega‑3 status include dry or scaly skin, brittle hair, increased susceptibility to inflammatory conditions, mood disturbances, and impaired wound healing. At the cellular level, insufficient EPA may disrupt eicosanoid balance, leading to a pro‑inflammatory state dominated by omega‑6 metabolites. This imbalance can exacerbate chronic inflammation and contribute to conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Clinical presentations may include joint stiffness and pain, prolonged inflammation after injury, and increased levels of inflammatory biomarkers like C‑reactive protein. Neurologically, low EPA levels have been associated with mood disorders, including depression and anxiety. Although research differentiates between EPA and DHA’s roles, some meta‑analyses suggest that EPA‑dominant supplementation may confer greater benefits for depressive symptoms, hinting that insufficient EPA could contribute to affective dysregulation. Infants and young children with very low marine omega‑3 intake may exhibit developmental deficits in visual acuity and cognitive function, although DHA is typically the focus of developmental research. Nonetheless, EPA’s anti‑inflammatory and membrane‑modulating actions complement DHA’s structural role in neural tissues. Individuals at risk for low EPA status include those who consume little or no fatty fish, strict vegetarians and vegans without algal omega‑3 supplementation, and individuals with conditions that increase lipid oxidation or turnover. Because EPA is prone to oxidation, diets high in processed foods and oxidative stress may further deplete tissue levels. Testing for omega‑3 status, through blood fatty acid profiling, can help identify deficient individuals and guide dietary or supplemental interventions.

EPA is found predominantly in marine sources, particularly oily fish and seafood, as well as in certain oils and fortified foods. The richest food sources of EPA are cold‑water, fatty fish that accumulate high levels of long‑chain omega‑3 fatty acids through their diet of microalgae and plankton. According to USDA nutrient data, Atlantic pickled herring provides approximately 1.18 grams of EPA per 1 cup serving, while Pacific herring offers around 0.824 grams per 3‑ounce portion. Similarly, canned pink salmon and coho salmon fillets contain substantial amounts, ranging from 0.7 to 0.46 grams EPA per 3‑ounce cooked serving. These foods not only deliver EPA but also DHA, creating a synergistic profile of marine omega‑3s. Other seafood items with notable EPA content include fish roe (such as black and red caviar), which provides over 0.7 grams EPA per ounce, and various types of mackerel, sardines, and anchovies that range widely in EPA concentration depending on preparation and species. Marine oils such as fish oil and seal oil remain concentrated sources of EPA and are often used in supplements; for example, menhaden fish oil contains upwards of 13 grams of EPA per 1 cup serving equivalent according to legacy USDA data. While plant foods do not contain appreciable EPA, some plant sources provide the precursor ALA, which the body can convert to EPA at low efficiency; examples include flaxseed, chia seeds, and walnuts, though their contribution to EPA status is limited without conversion. Including a variety of fatty fish in the diet at least twice per week aligns with dietary guidelines and helps ensure adequate EPA intake. Preparation methods such as grilling, baking, or broiling can preserve omega‑3 content, while avoiding overcooking that may oxidize these sensitive fats. For those who avoid fish, algal oil supplements offer a vegan source of EPA and DHA. Incorporating seafood with high EPA content alongside balanced meals supports not only omega‑3 status but also provides high‑quality protein, vitamin D, selenium, and other beneficial nutrients.

EPA absorption occurs in the small intestine following digestion of dietary lipids. Fats are emulsified by bile acids, allowing pancreatic lipases to hydrolyze triglycerides, freeing EPA for incorporation into micelles that facilitate uptake by enterocytes. Once inside intestinal cells, EPA is re‑esterified into triglycerides and phospholipids and packaged into chylomicrons for transport through the lymphatic system into bloodstream circulation. This process is highly efficient, with overall lipid absorption rates reported near 90–95% for long‑chain omega‑3 fatty acids. Dietary context influences absorption; consuming EPA with dietary fats enhances micelle formation and promotes uptake compared to low‑fat meals. Bioavailability of EPA can vary depending on its chemical form. For example, EPA in triglyceride form (as found in most natural fish oils) is generally well absorbed, while ethyl ester forms (often in some concentrated supplements) may require concurrent dietary fat to achieve equivalent absorption. Phospholipid‑bound EPA, as in krill oil, may offer enhanced bioavailability due to easier incorporation into cell membranes. Factors that inhibit absorption include intestinal malabsorption syndromes, fat‑restrictive diets, and lipid‑lowering medications such as bile acid sequestrants, which can bind bile acids and reduce micelle formation. Meanwhile, nutrients like fiber and plant sterols may modestly impede fat absorption by binding bile acids, although their impact on EPA status in the context of a balanced diet is generally minimal. Timing of intake with meals containing moderate fat enhances EPA uptake and incorporation into lipoproteins. Once absorbed, EPA competes with omega‑6 fatty acids for incorporation into cell membranes and for enzymes involved in eicosanoid synthesis; a lower dietary omega‑6 to omega‑3 ratio favors EPA incorporation and its downstream anti‑inflammatory effects. Chronic intake of EPA through regular consumption of fatty fish or supplements increases tissue levels, reflected in biomarkers like the omega‑3 index, which correlates EPA+DHA percentage in erythrocyte membranes with health outcomes.

Supplementation with EPA is often considered for individuals who do not consume adequate amounts of fatty fish or who have specific health conditions where increased omega‑3 intake may be beneficial. Fish oil supplements, which provide EPA and DHA in varying ratios, are the most common form. Algal oil supplements offer a vegetarian alternative, with some products providing EPA and DHA derived from microalgae. Clinical evidence supports EPA+DHA supplementation for lowering triglycerides, with doses of 2–4 grams per day under medical guidance commonly used in hypertriglyceridemia management. Additionally, certain prescription formulations such as EPA‑only or EPA‑DHA combinations are approved for cardiovascular risk reduction when lifestyle modifications alone are insufficient. Deciding whether to use supplements depends on dietary intake, health status, and individual goals. For healthy adults with regular fatty fish consumption, dietary sources may be sufficient to meet EPA+DHA targets. Individuals with cardiovascular risk factors, chronic inflammatory conditions, or low baseline omega‑3 status may benefit from supplementation, particularly when diet alone falls short. It is important to consider the quality of supplements; those with third‑party testing (e.g., USP or NSF certification) help ensure purity and potency, reducing the risk of contaminants such as heavy metals or oxidation products. Typical supplemental doses range from 250 mg to several grams of EPA+DHA daily, but higher doses should be supervised by healthcare providers due to potential bleeding risks and interactions with medications such as anticoagulants. For pregnant and lactating individuals, supplements can support maternal and fetal DHA status, with some products tailored for prenatal use containing balanced EPA and DHA. Timing of supplementation with meals containing dietary fat can enhance absorption. Ultimately, supplements should complement, not replace, a diet rich in natural food sources of omega‑3s, with individualized plans developed in consultation with clinicians and dietitians.

EPA toxicity from food sources alone is unlikely, but high supplemental intake can pose risks. The U.S. Food and Drug Administration suggests that supplemental EPA+DHA intake should not exceed 2 grams per day without medical supervision, although some guidelines permit up to 3 grams daily for combined EPA+DHA in healthy individuals. Doses above 5 grams per day are associated with increased bleeding risk, particularly in persons taking anticoagulants, due to EPA’s influence on platelet aggregation and clotting pathways. High intakes may also increase the risk of atrial fibrillation in certain individuals, with some evidence indicating a dose‑related effect when supplemental EPA and DHA exceed 1 gram per day in susceptible populations. Symptoms of excessive intake can include prolonged bleeding times, gastrointestinal upset, nausea, and increased risk of bruising. In cases of severe hypervitaminosis, very high doses over extended periods might impact immune function or oxidative stress, although such effects are rare. Monitoring of blood lipid profiles and clotting parameters can help guide safe supplementation in clinical settings, especially for individuals on blood thinners, those with bleeding disorders, or individuals preparing for surgery. It is also important to recognize that high intakes of omega‑3 supplements can interact with other medications, requiring careful coordination with healthcare providers.

EPA and omega‑3 supplements can interact with specific medications, mainly through effects on platelet function and lipid metabolism. The most clinically significant interactions occur with anticoagulants and antiplatelet agents such as warfarin, aspirin, and clopidogrel, where EPA’s anti‑aggregatory effects may enhance the risk of bleeding. Patients on these therapies should consult healthcare providers before initiating high‑dose EPA or omega‑3 supplementation. Additionally, EPA can influence blood pressure and may potentiate antihypertensive medications, leading to additive blood pressure‑lowering effects that require monitoring of blood pressure and dose adjustments. Some evidence suggests that omega‑3 supplements may interact with lipid‑lowering drugs, such as statins or fibrates, potentially augmenting triglyceride‑lowering effects. While this interaction is generally considered beneficial, clinicians often monitor lipid panels to tailor combined therapy. Rarely, high dosing of EPA/DHA could affect glucose metabolism in individuals with diabetes; careful blood glucose monitoring is advisable when initiating supplements in this population. Healthcare providers may also consider interactions with immunosuppressive medications, as high doses of omega‑3 fatty acids exert immunomodulatory effects that could influence immune response in complex conditions. Overall, communication between patients and clinicians regarding current medications, supplement use, and health goals is essential to mitigate drug interactions and optimize therapeutic outcomes.

Common Forms: Fish oil, Algal oil, EPA‑only prescription

Typical Doses: 250–500 mg EPA+DHA for general health; 1–4 g/day for specific conditions

When to Take: With meals to enhance absorption

Best Form: Triglyceride or phospholipid forms

⚠️ Interactions: Warfarin and other anticoagulants, Antihypertensives